Current developments in gene therapy for epidermolysis bullosa.

Area of Science:

• Genetics
• Dermatology
• Molecular Biology

Background:

• Epidermolysis bullosa (EB) is a severe monogenetic skin disease characterized by extreme blistering due to mutations affecting skin integrity proteins.
• Defects in genes encoding essential skin proteins lead to their functional impairment or absence in EB patients.

Purpose of the Study:

• To review the current landscape and future potential of DNA and RNA-based therapeutic strategies for epidermolysis bullosa.
• To highlight the necessity of developing novel treatment options for this debilitating genetic disorder.

Main Methods:

• Review of existing preclinical and clinical DNA/RNA therapy approaches for EB.
• Analysis of emerging gene therapy tools, including splicing-modulating therapies and designer nucleases.

Main Results:

• Several DNA/RNA therapies are under investigation for EB, with some already in clinical trials.
• cDNA replacement has shown success in a limited number of junctional EB patients.
• Splicing-modulating therapies, such as RNA trans-splicing and antisense oligonucleotides, demonstrate increasing efficiency and safety.

Conclusions:

• The genetic heterogeneity of EB necessitates diverse therapeutic strategies targeting DNA or RNA.
• Advanced gene therapy tools, particularly splicing-modulating techniques, represent a highly promising avenue for future EB treatment.
• Continued development of gene-based therapies is mandatory to provide effective treatment options for EB patients.